MDT perspectives on the limitations of standard of care immunotherapy for non-driver mutation metastatic NSCLC
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the challenges associated with standard-of-care immunotherapy for metastatic NSCLC without driver mutations, including treatment resistance and toxicity.
The multidisciplinary team:
Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK
Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA
Pathologist: Prof. Albrecht Stenzinger, University…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.